Skip to main content
19/10/2023

A single dose of attenuated vaccines could protect multiple sclerosis patients before starting immunosuppressive therapy

Dra. Mar Tintoré, Dr. René Carvajal i Dra. Susana Otero-Romero

Dr. Mar Tintoré, Dr. René Carvajal and Dr. Susana Otero-Romero.

19/10/2023

This strategy protects almost two thirds of patients. It also reduces the waiting time between vaccination and initiation of immune suppressive treatment.

In recent years, the approval and use of new background therapies for multiple sclerosis has led to a remarkable improvement in the modification of the evolution of the disease and in the accumulation of disability. These types of drugs decrease the function of the immune system. Consequently, they reduce flare-ups and new lesions against the brain and spinal cord, but at the same time, they increase the risk of infections.

"As a prevention strategy, it is recommended to vaccinate patients before administering immunosuppressive drugs", explains Dr. René Carvajal, neurologist at Cemcat and Vall d'Hebron and researcher in the Clinical Neuroimmunology group of the Vall d’Hebron Research Institute (VHIR). "Especially in the case of some vaccines, such as chickenpox or measles, which contain attenuated viruses, since in people whose immune system has been weakened by treatment, they can cause infection by the vaccine virus". The usual protocol consists of administering two doses of the vaccine, respecting the four-week interval between doses. In addition, after receiving the second dose, patients must wait another four weeks to start treatment, which means a delay of two months.

Single-dose immunization could reduce the waiting time, but it was not known whether this strategy would offer sufficient protection. To answer this question, Carvajal, along with other researchers, under the leadership of Dr. Mar Tintoré, neurologist and head of care at Cemcat, clinical head of the Neurology Service at the Vall d'Hebron University Hospital and principal researcher of the Clinical Neuroimmunology group at the VHIR, and Dr. Susana Otero-Romero, researcher at Cemcat, assistant physician at the Preventive Medicine Service at the Vall d’Hebron University Hospital and head of the Epidemiology and Public Health group at the VHIR, have carried out a study involving 96 patients with multiple sclerosis. The research, published in the Multiple Sclerosis Journal, compares the effectiveness of administering one dose versus the standard two-dose regimen.

According to the results, 66.6% of patients who received a single dose of measles or chickenpox had sufficient antibody levels to fight the infection. "In other words, the administration of a single dose of the vaccines protects two out of three patients", Otero-Romero remarked. As for the patients included in the standard group, almost all of them, 97.2%, acquired good levels of immunization.

In the words of Tintoré, "the study supports the strategy of vaccinating patients with a single dose, especially in those cases where it is necessary to start immunosuppressive treatment immediately. In addition, we also advocate implementing in clinical practice the analysis of antibody levels to confirm that the level of protection is adequate".

The work has counted with the collaboration of the Services of Preventive Medicine and Microbiology of the Vall d’Hebron University Hospital. It has also been possible thanks to the clinical grant awarded by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the research grant awarded by VHIR to René Carvajal and the funding received from the Instituto de Salud Carlos III.

Related news

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

Related professionals

Mar Tintore Subirana

Mar Tintore Subirana

Main researcher
Clinical Neuroimmunology
Read more
Susana Otero Romero

Susana Otero Romero

Head of group
Epidemiology and Public Health
Read more
Ingrid Galán Cartaña

Ingrid Galán Cartaña

Senior researcher
Clinical Neuroimmunology
Read more
Nuria  Martínez Sabaté

Nuria Martínez Sabaté

Administration and Management
Clinical Neuroimmunology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.